ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Clinical trials for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) explained in plain language.
Never miss a new study
Get alerted when new ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) trials appear
Sign up with your email to follow new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Massive study: Weight-Loss drug semaglutide slashes heart risks in real world
Disease control CompletedThis study looked at over 285,000 people with overweight or obesity to see if the weekly injection semaglutide (used for weight loss and diabetes) lowers the risk of heart problems like heart attacks, strokes, and death. Researchers analyzed medical records from 2016 to 2024. The…
Matched conditions: ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 26, 2026 05:06 UTC
-
Doctors' views on inflammation in heart and kidney disease surveyed
Knowledge-focused CompletedThis study surveyed 1,500 heart and kidney specialists in China to learn how they think about inflammation in patients with both heart and kidney disease. The goal was to understand their awareness and use of a blood test called hsCRP, which measures inflammation. No treatments w…
Matched conditions: ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated May 26, 2026 05:04 UTC
-
Prostate drug may shield heart, large study suggests
Knowledge-focused CompletedThis completed study looked at whether 5-alpha reductase inhibitors (5-ARIs), drugs used to treat an enlarged prostate, can also reduce the risk of heart disease caused by hardening of the arteries. Researchers analyzed health records from over 10,000 men in the UK and China. The…
Matched conditions: ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
Sponsor: Chinese PLA General Hospital • Aim: Knowledge-focused
Last updated May 22, 2026 13:51 UTC